肿瘤细胞治疗研究
英文原题：Therapeutic advances in the targeting of ROR1 in hematological cancers.
受体酪氨酸激酶（RTK）是参与细胞通讯和信号转导的关键细胞表面受体，在细胞生长、分化、存活和代谢中极为重要。
受体酪氨酸激酶（RTK）是参与细胞通讯和信号转导的关键细胞表面受体，对细胞生长、分化、存活和代谢具有重要作用。EGFR、VEGFR、HER2或ROR等RTK调节异常可导致多种疾病，尤其是癌症。ROR1已成为血液系统恶性肿瘤中一个有前景的靶点。ROR1靶向疗法不断发展，形成多种新型治疗方法，包括单克隆抗体、抗体药物偶联物、多种小分子药物和CAR T细胞，这些疗法均显示出令人鼓舞的临床前结果。在血液肿瘤领域，单克隆抗体、小分子药物、双特异性T细胞衔接器（BiTE）或CAR T细胞疗法均显示良好前景，临床试验数据支持应用抗ROR1疗法。本文旨在全面分析ROR1靶向疗法治疗血液系统恶性肿瘤的当前格局，介绍具有临床前和临床前景的创新策略。更好地理解ROR1的结构和功能特征，有望为靶向更广泛的恶性肿瘤提供新思路。
Receptor tyrosine kinases (RTKs) are key cell surface receptors involved in cell communication and signal transduction, with great importance in cell growth, differentiation, survival, and metabolism. Dysregulation of RTKs, such as EGFR, VEGFR, HER2 or ROR, could lead to various diseases, particularly cancers. ROR1 has emerged as a promising target in hematological malignancies. The development of ROR1 targeted therapies is continuously growing leading to remarkable novel therapeutical approaches using mAbs, antibody-drug conjugates, several small molecules or CAR T cells which have shown encouraging preclinical results. In the hematological field, mAbs, small molecules, BiTEs or CAR T cell therapies displayed promising outcomes with the clinical trials data encouraging the use of anti-ROR1 therapies. This paper aims to offer a comprehensive analysis of the current landscape of ROR1-targeted therapies in hematological malignancies marking the innovative approaches with promising preclinical and clinical. Offering a better understanding of structural and functional aspects of ROR1 could lead to new perspectives in targeting a wide spectrum of malignancies.
MEMBER ACCOUNT
登录成功会直接打开下一页。
